Core Viewpoint - The stock price of Canar Medical Co., Ltd. closed at 24.22 yuan on August 20, 2025, reflecting a decrease of 0.14 yuan or 0.57% from the previous trading day [1] Company Overview - Canar Medical operates in the medical device sector, focusing on the research, production, and sales of medical products, veterinary products, and laboratory consumables [1] - In the 2024 annual report, medical products accounted for 51.23% of the company's revenue, while veterinary products made up 39.03% [1] Recent Developments - On August 20, 2025, Canar Medical announced that its wholly-owned subsidiary, Jiangsu Canar Medical Technology Co., Ltd., received three utility model patent certificates from the National Intellectual Property Administration. The patents include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe," all of which are related to the company's main business products [1] Financial Performance - On August 20, 2025, the main funds experienced a net outflow of 716,700 yuan, with a cumulative net outflow of 4,222,500 yuan over the past five days [1]

Group 1 - Weicai Technology achieved a net profit of 101 million yuan in the first half of 2025, a year-on-year increase of 831.03% [1] - The company reported an operating income of 634 million yuan, up 47.53% year-on-year, with a basic earnings per share of 0.68 yuan [1] - Weicai Technology specializes in wafer testing, chip finished product testing, and related integrated circuit testing services [1] Group 2 - Changhua Group received a project development notification from a domestic automotive company, with an expected total sales amount of approximately 190 million yuan over an 8-year lifecycle [2] - The project is set to begin mass production in the third quarter of 2026 [2] - Changhua Group focuses on the research, production, and sales of automotive metal components [2][3] Group 3 - Junhe Co. reported a net profit of 30.99 million yuan in the first half of 2025, a year-on-year decrease of 19.53% [3] - The company achieved an operating income of 578 million yuan, up 5.53% year-on-year, with a basic earnings per share of 0.08 yuan [3][4] - Junhe Co. specializes in the research, design, manufacturing, and sales of household water pumps and their accessories [4] Group 4 - Tonghua Jinma reported a net profit of 16.80 million yuan in the first half of 2025, a year-on-year increase of 34.77% [5] - The company achieved an operating income of 650 million yuan, a slight increase of 0.12% year-on-year, with a basic earnings per share of 0.0174 yuan [5] - Tonghua Jinma focuses on the research, production, and sales of pharmaceutical products [5][6] Group 5 - Xing Shuai reported a net profit of 122 million yuan in the first half of 2025, a year-on-year increase of 31.79% [8] - The company achieved an operating income of 1.132 billion yuan, up 8.59% year-on-year, with a basic earnings per share of 0.37 yuan [8] - Xing Shuai specializes in the research, production, and sales of various types of refrigeration compressor thermal protectors, starters, and temperature controllers [8] Group 6 - Ice Wheel Environment reported a net profit of 266 million yuan in the first half of 2025, a year-on-year decrease of 19.71% [9] - The company achieved an operating income of 3.118 billion yuan, down 6.92% year-on-year, with a basic earnings per share of 0.27 yuan [9] - Ice Wheel Environment focuses on the research, design, and sales of artificial environment control technology and energy comprehensive utilization technology [9][10] Group 7 - Jiangsu Huachen reported a net profit of 47.27 million yuan in the first half of 2025, a year-on-year increase of 18.37% [18] - The company achieved an operating income of 938 million yuan, up 40.46% year-on-year, with a basic earnings per share of 0.2901 yuan [18] - Jiangsu Huachen specializes in the research, production, and sales of energy-saving transformers and smart electrical equipment [18] Group 8 - Hanma Technology reported a net profit of 27.73 million yuan in the first half of 2025, reversing from a loss of 153 million yuan in the same period last year [18] - The company achieved an operating income of 2.847 billion yuan, a year-on-year increase of 50.03% [18] - Hanma Technology focuses on the production, research, and sales of heavy trucks, special vehicles, and automotive components [18] Group 9 - Tianyue Advanced announced the listing of its H-shares on the Hong Kong Stock Exchange, raising approximately 1.938 billion HKD [19] - The global offering consisted of 47.7457 million shares, with a price of 42.80 HKD per share [19] - Tianyue Advanced specializes in the research, production, and sales of silicon carbide semiconductor materials [19][20] Group 10 - Kesi Technology signed a sales framework contract worth up to 401 million yuan with Beijing Tianyuan Innovation Technology Co., Ltd. [21] - The contract is valid for two years and involves a comprehensive information integration service project [21] - Kesi Technology focuses on the research, development, manufacturing, and sales of electronic information equipment [21][22]

Core Viewpoint - The company, Canar Medical Technology Co., Ltd., a wholly-owned subsidiary of Canar Co., has recently received three utility model patent certificates from the National Intellectual Property Administration of China, indicating a significant advancement in its product offerings [1] Group 1 - The patents awarded include "A Pressure-Resistant Anti-Backflow Infusion Pipeline," "Pressure Display Syringe," and "Fixed Measurement Syringe," showcasing the company's innovation in medical technology [1]

Group 1 - The core point of the article is that Canar Medical Technology Co., Ltd., a wholly-owned subsidiary of Canar Co., has recently received patent certificates from the National Intellectual Property Administration for three medical products [2] - The patents granted include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe" [2] - For the fiscal year 2024, Canar's revenue composition is as follows: medical products account for 51.23%, veterinary products for 39.03%, laboratory consumables for 7.61%, and others for 2.13% [2]

证券代码：301122 证券简称：采纳股份 公告编号：2025-076 采纳科技股份有限公司 关于全资子公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）全资子公司江苏采纳医疗科技 有限公司（以下简称"采纳医疗"），于近日收到国家知识产权局颁发的专利证 书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | --- | --- | --- | --- | --- | --- | | 1 | 一种耐压防逆流输 | 实用新型 | ZL | 采纳医疗 | 2025年08月 | | | 液管路 | | 202421897663.3 | | 19 日 | | 2 | 压力显示注射器 | 实用新型 | ZL | 采纳医疗 | 2025年08月 | | | | | 202421897901.0 | | 19 日 | | 3 | 固定计量注射器 | 实用新型 | ZL | 采纳医疗 | 2025年08月 | | | | | 202421898995.3 | | 1 ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-075 采纳科技股份有限公司 关于使用部分闲置募集资金和自有资金 进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险 的前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含 超募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内， 资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披 ...

归创通桥(02190)发布公告，于2025年8月19日，董事会审议及批准有关建议采纳股份（301122）激励计 划的决议案。股份激励计划将以发行新H股(包括转让库存股)拨资，因而构成《上市规则》第十七章所 界定涉及公司发行新股份的股份计划。采纳股份激励计划须待股东批准后，方可作实。 ...

Core Viewpoint - The company, Zhichuang Tongqiao (02190), announced the approval of a proposed share incentive plan by its board of directors, which is set to be reviewed on August 19, 2025, and requires shareholder approval to be implemented [1] Group 1 - The share incentive plan will involve the issuance of new H-shares, including the transfer of treasury shares, thus constituting a share plan as defined under Chapter 17 of the Listing Rules [1] - The implementation of the share incentive plan is contingent upon receiving approval from the shareholders [1]

Group 1 - The stock price of CaiNa Co., Ltd. was 23.57 yuan as of August 14, 2025, down 0.97 yuan or 3.95% from the previous trading day's closing price [1] - The company operates in the medical device sector, focusing on the research, production, and sales of medical devices [1] - On August 14, 2025, a block trade occurred involving 1.6575 million shares at a transaction value of 33.9953 million yuan, with a transaction price of 20.51 yuan, representing a 12.98% discount to the closing price [1] Group 2 - The block trade accounted for 52.90% of the total transaction value on that day [1] - On August 14, 2025, the net outflow of main funds for CaiNa Co., Ltd. was 703,900 yuan, which is 0.04% of the circulating market value [1] - Over the past five days, the net outflow of main funds totaled 21.9651 million yuan, representing 1.38% of the circulating market value [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交全额 买方营业部 (万元) | | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-14 | 301122 | 采纳股份 | 20.51 | 165.75 | 3,399.53 万宏源证券有限 | | 机构专用 | | | | | | | | 公司上海金山区蒙 | | | | | | | | | 山路证券营业部 | | 8月14日，采纳股份大宗交易成交165.75万股，成交额3399.53万元，占当日总成交额的34.6%，成交价20.51元，较市场收盘 价23.57元折价12.98%。 ...